ALSO NOTED: J&J recalls balloon catheters; Dr. Reddy's stock tanks on loss;

> Johnson & Johnson is recalling 132,000 balloon catheters used to expand blood vessels after it determined that problems with them could cause injury or death; there have been no reported deaths, however. Report

> Dr. Reddy's stock took a tumble in India after the company reported an unexpected $21.5 million loss on declining revenues in the most recent quarter. Report

> Kidnapped January 18, Nicholas Piramal executive Ashwini Bhatt was rescued by a special police task force on Saturday, and the gangs responsible have been identified. Report

> Consumer advocates are asking the FDA to pin more stringent warnings on the wrinkle-fighting drug Botox, citing "serious adverse reactions, including death." Report

> GlaxoSmithKline is the first of the UK's top companies to offer its employees the chance to invest their own pension funds. Report

> Glenmark Pharma got the FDA's clearance for its manufacturing plant in Baddi, India, which makes semi-solid products. Report

> Sanofi-Aventis announced that Japanese regulators cleared its clot-prevention drug Clexane. Report

And Finally... Too much coffee may worsen diabetes, according to a new study in Diabetes Care. Report

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.